Oncimmune Targets Age-Related Diseases with Biomarker Research.

23 April 2024

  • ImmunoINSIGHTS is the leading antibody marker discovery platform which will now be used to research novel biomarkers associated with ageing and ageing-related conditions.
  • The discovery of novel biomarkers helps recruit the right patients for clinical trials, as well as monitoring disease progression and response to interventions
  • Applying insights from Oncimmune’s platform will ultimately support researchers working towards better diagnosis and treatments for ageing-related conditions.

Oncimmune Holdings plc (AIM: ONC.L) (“Oncimmune” or the “Company”), a leading autoantibody profiling company to the pharmaceutical and biotechnology industry enabling precision medicine, is extending the focus of its advanced autoantibody platform technology to research biomarkers for ageing-related diseases.

This move into supporting clinical trials and research into ageing and age-related disease reflects Oncimmune’s commitment to address the profound challenges associated with ageing, where it believes it can make meaningful contributions to accelerate precision medicine. The company is already working with leading drug discovery companies on ageing-related research and has been approached by several global pharmaceutical companies about the use of its technology in this field.

As longevity increases, the immune system undergoes changes known as immunosenescence, which can contribute to the development of age-related diseases.  A significant factor that contributes to the development of age-related diseases is the increased production of autoantibodies – antibodies that mistakenly target the body’s own tissue.

These autoantibodies play an important role in various autoimmune disorders such as rheumatoid arthritis, lupus and autoimmune thyroid diseases, which can become more prevalent with age. Additionally, autoantibodies can contribute to chronic inflammation, a hallmark of many age-related conditions including cardiovascular disease, neurodegenerative diseases (such as Alzheimer’s and Parkinson’s) and diabetes. Oncimmune’s work in these disease areas has already contributed to discoveries such as biomarkers for early treatment of rheumatoid arthritis1 and diagnosis of systemic sclerosis.2

Oncimmune is focusing more specifically on the role autoantibodies play in age-related diseases as a whole and different trajectories of ageing.  Working with its partners to unravel the complex interplay between autoantibodies and ageing-related conditions, Oncimumme is aiming to identify and validate novel biomarkers associated with such conditions, enabling more targeted intervention and personalised medicine.

Oncimmune’s technology can be used to support clinical trials recruiting patients with an early onset of age-related conditions, monitoring disease progression and response to interventions, thus helping to identify potentially new therapeutic targets.

Oncimmune’s CEO, Martin Gouldstone, will speak on how ImmunoINSIGHTS can support clinical trials in the Pioneer Presents event on Healthy Ageing on the 24th of April at the Kent Science Park.

Martin Gouldstone, Oncimmune’s Chief Executive Officer, said: As ageing-related diseases become more prevalent in society we believe that our ImmunoINSIGHTS technology can be instrumental in finding better diagnosis and treatment solutions for these diseases, while making clinical trials more efficient and productive.  We are working closely with our partners in this area and I look forward to discussing the topic with world-leading experts later this month.


  1. Vordenbäumen S, Brinks R, et al. (2020). Profiling of IgG antibodies targeting unmodified and corresponding citrullinated autoantigens in a multicenter national cohort of early arthritis in Germany. Arthritis Research & Therapy, 22(1), 167. doi: 10.1186/s13075-020-02252-6
  2. Fritzler MJ, et al. (2018). Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype. Autoimmun Rev, 17(3), 267-275. doi: 10.1016/j.autrev.2018.01.006


For further information contact: